1. Home
  2. MATH vs ACET Comparison

MATH vs ACET Comparison

Compare MATH & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MATH
  • ACET
  • Stock Information
  • Founded
  • MATH 2015
  • ACET 1947
  • Country
  • MATH Hong Kong
  • ACET United States
  • Employees
  • MATH N/A
  • ACET N/A
  • Industry
  • MATH Finance/Investors Services
  • ACET Biotechnology: Pharmaceutical Preparations
  • Sector
  • MATH Finance
  • ACET Health Care
  • Exchange
  • MATH Nasdaq
  • ACET Nasdaq
  • Market Cap
  • MATH 60.8M
  • ACET 60.5M
  • IPO Year
  • MATH N/A
  • ACET N/A
  • Fundamental
  • Price
  • MATH $3.28
  • ACET $0.72
  • Analyst Decision
  • MATH
  • ACET Strong Buy
  • Analyst Count
  • MATH 0
  • ACET 7
  • Target Price
  • MATH N/A
  • ACET $5.60
  • AVG Volume (30 Days)
  • MATH 142.4K
  • ACET 711.9K
  • Earning Date
  • MATH 10-30-2025
  • ACET 11-05-2025
  • Dividend Yield
  • MATH N/A
  • ACET N/A
  • EPS Growth
  • MATH N/A
  • ACET N/A
  • EPS
  • MATH 0.41
  • ACET N/A
  • Revenue
  • MATH $44,567,257.00
  • ACET N/A
  • Revenue This Year
  • MATH N/A
  • ACET N/A
  • Revenue Next Year
  • MATH N/A
  • ACET N/A
  • P/E Ratio
  • MATH $8.00
  • ACET N/A
  • Revenue Growth
  • MATH 165.86
  • ACET N/A
  • 52 Week Low
  • MATH $0.80
  • ACET $0.45
  • 52 Week High
  • MATH $4.17
  • ACET $1.63
  • Technical
  • Relative Strength Index (RSI)
  • MATH 56.90
  • ACET 51.76
  • Support Level
  • MATH $3.05
  • ACET $0.69
  • Resistance Level
  • MATH $3.35
  • ACET $0.75
  • Average True Range (ATR)
  • MATH 0.21
  • ACET 0.05
  • MACD
  • MATH 0.07
  • ACET 0.00
  • Stochastic Oscillator
  • MATH 89.23
  • ACET 59.79

About MATH Metalpha Technology Holding Limited

Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and derives a majority of its revenue from Hong Kong.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: